Drugs / MucoCept-CVN
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT07181486 Comparator | Oct 2025 → Feb 2027 expected | HIV infectious disease | Craig Cohen, MD, MPH | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MucoCept-CVN | “MucoCept-CVN is supplied as a prefilled vaginal applicator containing Lactobacillus jensenii 1153-1666, a modified strain of L. jensenii 1153 by integrating a modified...” NCT07181486 ↗ |
| Action | Inhibit | “potent HIV entry inhibitor” NCT07181486 ↗ |
| Modality | Other / unclassified | “modified into a live biotherapeutic product (LBP)” NCT07181486 ↗ |
| Route | Other | “The vaginally administered MucoCept-CVN contains Lactobacillus jensenii 1153-1666” NCT07181486 ↗ |